To transform cancer care through precision oncology. Leveraging advanced molecular science, we aim to make non-invasive blood tests accessible for improved cancer management, especially for those facing advanced cancer.
At Datar Cancer Genetics, we are dedicated to supporting you every step of the way with precision and care.
At Datar Cancer Genetics, we believe that relentless research, bold initiatives, sustained commitment, and an unwavering determination to overcome cancer are essential in making a meaningful impact. This dedication drives us to pioneer new methods and continuously innovate, focusing on the power of molecular oncology and personalised medicine to transform cancer care.
Our non-invasive blood-based tests are designed to help clinicians make informed, data-driven decisions, enabling personalised cancer therapies that improve patient outcomes. By staying at the forefront of precision oncology, we strive to bring cutting-edge and accessible solutions to patients worldwide.
Since our foundation in India, we have been dedicated to advancing non-invasive cancer detection and personalised therapies.
Began pioneering research on Circulating Tumour Cells (CTCs) to create non-invasive methods for early cancer detection and treatment guidance
Expanded our reach to Germany and established a laboratory in the UK to bring our innovative solutions closer to patients worldwide.
Reached key milestones, including FDA approval for TriNetra™- Breast, a blood test to screen for breast cancer, and UK recognition for Trublood™-Prostate, a non-invasive test for prostate cancer diagnosis.
Promoter, Datar Cancer Genetics
[B.Sc., LLB]
Senior Director
[BSc, LLB, Healthcare Management (ISB)]
Senior Director
[MD, FRCP (Glasg.), MCEM, FRSPH (CMQ/ASG)]
Senior Director
[MD (Pathology), MMO (CNIO)]
Director
[LLB]
Director, Research and Innovation
[PhD (Biotechnology), MMO (CNIO)]
Chief Scientific Officer (USA)
[Chemical Engineering), PhD]
General Manager, Scientific Affairs and Communications
[PhD (Biotechnology)]
Managing Director, Europe
[PhD (Medicinal Chemistry)]
Director, Applications
[MBBS, MRCOG, D OBS]
Consultant Pathologist
[MD (Pathology)]
Laboratory Director (CLIA)
[PhD (Chemistry)]
Senior Manager
[MSc (Microbiology), PhD (Medical Microbiology)]
Laboratory Director
[PhD (Biochemistry)]
Medical Oncologist
[BSc, PhD, MBBS, MRCP, FRCP]
Medical Oncologist
[MD, MRCP, FRCR]
Breast Cancer Surgeon
[MS, FRCS]
Medical Oncologist
[MA, MD, FRCP, FRCR]
Medical Oncologist
[MD, FACP]
Medical Oncologist
[MBBS, MD, MS]
Neurosurgeon
[MBBS, FRCS, FAMS (Neurosurgery), FRCS, FACS]
Medical Oncology
[MBBS, MD (General Medicine), DM (Medical Oncology)]
Medical Oncologist
[MBBS, DNB, MRCP, FRCP]
Breast Cancer Surgeon
[MBBS, MRCS (UK)]
Medical Oncologist
[MBBS, MD]
Promoter, Datar Cancer Genetics
[B.Sc., LLB]
Senior Director
[BSc, LLB, Healthcare Management (ISB)]
Senior Director
[MD, FRCP (Glasg.), MCEM, FRSPH (CMQ/ASG)]
Senior Director
[MD (Pathology), MMO (CNIO)]
Director
[LLB]
Director, Research and Innovation
[PhD (Biotechnology), MMO (CNIO)]
Chief Scientific Officer (USA)
[Chemical Engineering), PhD]
General Manager, Scientific Affairs and Communications
[PhD (Biotechnology)]
Managing Director, Europe
[PhD (Medicinal Chemistry)]
Director, Applications
[MBBS, MRCOG, D OBS]
Consultant Pathologist
[MD (Pathology)]
Laboratory Director (CLIA)
[PhD (Chemistry)]
Senior Manager
[MSc (Microbiology), PhD (Medical Microbiology)]
Laboratory Director
[PhD (Biochemistry)]
Medical Oncologist
[BSc, PhD, MBBS, MRCP, FRCP]
Medical Oncologist
[MD, MRCP, FRCR]
Breast Cancer Surgeon
[MS, FRCS]
To fulfill our vision, we have developed a range of non-invasive blood tests that provide personalised insights to guide cancer treatment, helping doctors make informed decisions tailored to each patient.